Forte Biosciences (FBRX) Peer Comparison

$76.99

$0.00 (0.00%)

As on 28-Aug-2026 09:30EDT

Market cap

$1,634 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

8.9

Div. Yield

0 %

Edit

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	1,634	16,765	16,261	13,492	12,332
Revenue ($ Mln)	--	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-87.94	491.50	755.85	860.62	-325.10
Net Margin (%)	--	17.67	71.69	35.33	-25.32
RoE (%)	-71.85	110.09	--	42.98	-57.72
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	8.89	39.29	9.76	7.42	23.98

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	0.00	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	-0.01	1,982.07	103.47	85.67	109.42
Gross Profit	-0.06	760.62	588.53	2,236.43	902.26
Operating Expenses	90.02	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-90.00	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-86.33	598.92	101.11	1,035.47	-325.10
Provision for Tax	1.60	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-87.94	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	183.79	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	1.66	187.89	384.48	288.55	346.72
Current Liabilities	20.29	1,435.43	464.70	361.93	374.20
Total Liabilities	82.78	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	2.64	1,006.90	895.24	1,243.41	45.47
Current Assets	203.10	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	82.78	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	0.00	120.10	449.89	165.93	347.75
Net Current Assets	0.00	-385.14	0.00	888.90	824.98

Cashflow ($ Mln)

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-50.88	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	36.23	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	69.36	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-122.28	53.56	-30.01	32.82	-31.49
ROE (%)	-71.85	110.09	163.18	42.98	-57.72
ROA (%)	-33.45	15.64	26.53	29.32	-22.97
EBIT Margin (%)	--	21.13	5.73	31.04	-18.97
Net Margin (%)	--	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	--	24.67	114.85	9.23	149.04
EBIT Growth (%)	-48.86	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	-107.14	17.50	378.76	42.89	-15.32
EPS Growth (%)	42.41	26.84	353.27	50.42	-0.64
Book Value Growth (%)	-7.98	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-7.02	36.06	-59.76	15.79	-45.32
Price / Book Value	7.99	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-6.01	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.00	0.00	0.65
Short term debt to equity ratio	0.00	0.00	0.05	0.00	0.00
Current Ratio	10.01	0.73	2.99	3.46	3.20
Quick Ratio	10.01	0.73	2.32	3.38	2.94
Interest Coverage	--	--	1.62	--	-19.80

Operating Efficiency Ratios

	Forte Biosciences (FBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	--	15.88	21.25	13.74	14.98
Asset Turnover	0.00	0.89	0.37	0.83	0.91
Receivable days	--	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	42,426.07	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly